
Lynda Stranix-Chibanda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8888118/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Maternal Human Immunodeficiency Virus (HIV) Drug Resistance Is Associated With Vertical Transmission and Is Prevalent in Infected Infants. Clinical Infectious Diseases, 2022, 74, 2001-2009.	2.9	7
2	Where are the pregnant and breastfeeding women in new pre-exposure prophylaxis trials? The imperative to overcome the evidence gap. Lancet HIV,the, 2022, 9, e214-e222.	2.1	19
3	The potential effect of pre-exposure prophylaxis (PrEP) roll-out on sexual-risk behaviour among adolescents and young people in East and southern Africa. African Journal of AIDS Research, 2022, 21, 1-7.	0.3	3
4	Effects of long-term antiretroviral therapy in reproductive-age women in sub-Saharan Africa (the) Tj ETQq0 0 0 rg e394-e403.	BT /Overlo 2.1	ck 10 Tf 50 6 5
5	Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa. Clinical Infectious Diseases, 2021, 73, e1893-e1900.	2.9	35
6	Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial. PLoS ONE, 2021, 16, e0246272.	1.1	6
7	Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial, Lancet, The, 2021, 397, 1276-1292.	6.3	82
8	Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial. PLoS ONE, 2021, 16, e0255250.	1.1	2
9	Association of Maternal Viral Load and CD4 Count With Perinatal HIV-1 Transmission Risk During Breastfeeding in the PROMISE Postpartum Component. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 206-213.	0.9	22
10	Emerging evidence from a systematic review of safety of preâ€exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading?. Journal of the International AIDS Society, 2020, 23, e25426.	1.2	67
11	Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science framework. Lancet HIV,the, 2020, 7, e582-e592.	2.1	44
12	Slow Acceptance of Universal Antiretroviral Therapy (ART) Among Mothers Enrolled in IMPAACT PROMISE Studies Across the Globe. AIDS and Behavior, 2019, 23, 2522-2531.	1.4	5
13	Factors associated with unsuppressed viremia in women living with HIV on lifelong ART in the multi-country US-PEPFAR PROMOTE study: A cross-sectional analysis. PLoS ONE, 2019, 14, e0219415.	1.1	11
14	Extended Prophylaxis With Nevirapine Does Not Affect Growth in HIV-Exposed Infants. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 377-385.	0.9	7
15	Title is missing!. , 2019, 14, e0219415.		0
16	Title is missing!. , 2019, 14, e0219415.		0
17	Title is missing!. , 2019, 14, e0219415.		0

#	Article	IF	CITATIONS
19	Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-Label, Clinical Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 383-392.	0.9	115
20	Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial. HIV Clinical Trials, 2018, 19, 209-224.	2.0	10
21	Shedding of Oral Poliovirus Vaccine (OPV) by HIV-Infected and -Uninfected Mothers of OPV-Vaccinated Zimbabwean Infants. Journal of the Pediatric Infectious Diseases Society, 2017, 6, piv083.	0.6	5
22	Advanced Analysis Techniques Improve Infant Bone and Body Composition Measures by Dual-Energy X-Ray Absorptiometry. Journal of Pediatrics, 2017, 181, 248-253.e3.	0.9	12
23	Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, S145-S153.	0.9	29
24	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 573-575.	0.9	36
25	Group Problem-Solving Therapy for Postnatal Depression among HIV-Positive and HIV-Negative Mothers in Zimbabwe. Journal of the International Association of Providers of AIDS Care, 2014, 13, 335-341.	0.6	63
26	Integrating family planning and prevention of mother to child HIV transmission in Zimbabwe. Contraception, 2014, 89, 209-214.	0.8	26
27	Optimization of the oligonucleotide ligation assay for the detection of nevirapine resistance mutations in Zimbabwean Human Immunodeficiency Virus type-1 subtype C. Journal of Virological Methods, 2014, 210, 36-39.	1.0	11
28	Efficacy and Safety of an Extended Nevirapine Regimen in Infants of Breastfeeding Mothers With HIV-1 Infection for Prevention of HIV-1 Transmission (HPTN 046). Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 366-374.	0.9	24
29	Vaccine Poliovirus Shedding and Immune Response to Oral Polio Vaccine in HIV-Infected and -Uninfected Zimbabwean Infants. Journal of Infectious Diseases, 2013, 208, 672-678.	1.9	25
30	Hematologic and Immunologic Parameters in Zimbabwean Infants: A Case for Using Local Reference Intervals to Monitor Toxicities in Clinical Trials. Journal of Tropical Pediatrics, 2012, 58, 59-62.	0.7	13
31	Extended prophylaxis with nevirapine and cotrimoxazole among HIV-exposed uninfected infants is well tolerated. Aids, 2012, 26, 325-333.	1.0	12
32	Immunologic Response to Oral Polio Vaccine in Human Immunodeficiency Virus–infected and Uninfected Zimbabwean Children. Pediatric Infectious Disease Journal, 2012, 31, 176-180.	1.1	28
33	Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2012, 379, 221-228.	6.3	108
34	Factors Associated With Repeat Pregnancy Among Women in an Area of High HIV Prevalence in Zimbabwe. Women's Health Issues, 2011, 21, 222-229.	0.9	16
35	Validation of the Edinburgh Postnatal Depression Scale among women in a high HIV prevalence area in urban Zimbabwe. Archives of Women's Mental Health, 2010, 13, 201-206.	1.2	94
36	Factors associated with access to HIV care and treatment in a prevention of mother to child transmission programme in urban Zimbabwe. Journal of the International AIDS Society, 2010, 13, 38-38.	1.2	38

#	Article	IF	CITATIONS
37	Postnatal Depression by HIV Status Among Women in Zimbabwe. Journal of Women's Health, 2010, 19, 2071-2077.	1.5	54
38	The feasibility of preventing mother-to-child transmission of HIV using peer counselors in Zimbabwe. AIDS Research and Therapy, 2008, 5, 17.	0.7	37
39	Screening for Psychological Morbidity in HIV-Infected and HIV-Uninfected Pregnant Women Using Community Counselors in Zimbabwe. Journal of the International Association of Providers of AIDS Care, 2005, 4, 83-88.	1.2	26